Skip to main content
. Author manuscript; available in PMC: 2021 Apr 1.
Published in final edited form as: Invest New Drugs. 2019 May 7;38(2):457–467. doi: 10.1007/s10637-019-00783-7

Fig. 2.

Fig. 2

Antitumor activity of GSK3052230 in combination with standard therapy in treatment-naive MPM patients. a Maximum percentage decrease from baseline in target lesions according to mRECIST 1.1 criteria. *Maximum percentage decrease from baseline = 0%. †Subject withdrawn from study for surgical resection. b Swimplot demonstrating duration of treatment and best confirmed response. PR, partial response; SD, stable disease; yellow box, first occurrence of PR; yellow triangle, ongoing patients as of 17-March-2017. *Subject withdrawn from study for surgical resection